The 5-year Postmenopausal Evaluation and Risk-reduction with Lasofoxifene study (n = 8,556) demonstrated an 81% reduction in risk of total ER+ breast cancer and an 83% reduction in risk of invasive ER+ breast cancer with LAS 0.5 mg/day versus PBO (P <0.001) [77]. Here, ESR1 is linked to breast cancer.